Electra Meccanica Partners with Engel & Vlkers to Launch SOLO Carsharing Initiative at Canadian Residential Development

VANCOUVER, British Columbia, Nov. 12, 2018 (GLOBE NEWSWIRE) — ElectraMeccanica Vehicles Corp. (NASDAQ: SOLO) (“Electra Meccanica” or the “Company”), a designer and manufacturer of electric vehicles, today announced a first-of-kind partnership with Engel & Völkers’ proposed Chantrell Creek Estates residential development in British Columbia, Canada to introduce a SOLO electric vehicle carsharing program to provide … Continue reading “Electra Meccanica Partners with Engel & Vlkers to Launch SOLO Carsharing Initiative at Canadian Residential Development”

Cray Turbocharges AI Model Development With New Algorithms and Frameworks

Urika Software Suite Features Unique Hyperparameter Optimization; Empowers Customers with Added AI Tools SEATTLE, Nov. 12, 2018 (GLOBE NEWSWIRE) — Global supercomputer leader Cray Inc. (Nasdaq:CRAY) today announced enhancements to its Urika® AI and Analytics software suites, adding tools that enable data scientists to train artificial intelligence (AI) models more accurately and in less time. New … Continue reading “Cray Turbocharges AI Model Development With New Algorithms and Frameworks”

Mersana Therapeutics Presents Pre-clinical Data at AACR-NCI-EORTC on Two Additional, Proprietary Antibody Drug Conjugate Platforms and a Pre-clinical Update for XMT-1522 in Non-small Cell Lung Cancer

CAMBRIDGE, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin® and other proprietary platforms, today announced it will present data on two new, novel antibody-drug conjugate (ADC) platforms at the AACR-NCI-EORTC International Conference on … Continue reading “Mersana Therapeutics Presents Pre-clinical Data at AACR-NCI-EORTC on Two Additional, Proprietary Antibody Drug Conjugate Platforms and a Pre-clinical Update for XMT-1522 in Non-small Cell Lung Cancer”

VistaGen Therapeutics Receives Notices of Allowance in Australia and Japan for AV-101 Patents Covering Treatment of Depression

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2018 (GLOBE NEWSWIRE) — VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced receiving Notices of Allowance  from IP Australia and the Japan Patent Office (JPO) related to methods of treating depression … Continue reading “VistaGen Therapeutics Receives Notices of Allowance in Australia and Japan for AV-101 Patents Covering Treatment of Depression”

Cellectar Announces FDA Grants Exemption to Import Alert for CLR 131 Hematology Studies

Clinical Trials to Advance Across Multiple Hematology Programs FLORHAM PARK, N.J., Nov. 12, 2018 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces today that the U.S. Food and Drug Administration (FDA) has granted an exemption to … Continue reading “Cellectar Announces FDA Grants Exemption to Import Alert for CLR 131 Hematology Studies”

Hi-Crush Announces Integrated Agreement for Northern White Frac Sand with Chesapeake Energy

HOUSTON, Nov. 12, 2018 (GLOBE NEWSWIRE) — Hi-Crush Partners LP (NYSE: HCLP), or “Hi-Crush”, today announced that it has entered into a new, long-term frac sand supply agreement for the in-basin purchase of Northern White frac sand to support Chesapeake Energy Corporation (“Chesapeake”) and their completions program in the Marcellus and Powder River Basins. In … Continue reading “Hi-Crush Announces Integrated Agreement for Northern White Frac Sand with Chesapeake Energy”

Achaogen Announces Review of Strategic Alternatives and Corporate Restructuring

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) — Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that it has begun a review of strategic alternatives to maximize shareholder value, including but not limited to the potential sale or … Continue reading “Achaogen Announces Review of Strategic Alternatives and Corporate Restructuring”

FlexShopper, Inc. Reports 2018 Third Quarter Financial Results Highlighted by 90% Growth in Lease Originations and 27% Revenue Growth

Company Provides 2019 Guidance BOCA RATON, Fla., Nov. 05, 2018 (GLOBE NEWSWIRE) — FlexShopper, Inc. (Nasdaq:FPAY) (“FlexShopper”), a leading national online lease-to-own (“LTO”) retailer and LTO payment solution provider, today announced its financial results for the quarter ended September 30, 2018, highlighted by record third quarter revenue and lease originations. Results for Three Months Ended September 30, 2018 vs. … Continue reading “FlexShopper, Inc. Reports 2018 Third Quarter Financial Results Highlighted by 90% Growth in Lease Originations and 27% Revenue Growth”

RaceTrac Names Cardtronics Exclusive Provider of ATM Services for Dallas-Ft. Worth Stores

Credit Union of Texas set to brand all ATMs at RaceTrac stores in North Texas Metroplex HOUSTON, Nov. 05, 2018 (GLOBE NEWSWIRE) — Cardtronics (Nasdaq: CATM) is now the exclusive provider of ATM services to 121 RaceTrac convenience stores in the Dallas-Ft. Worth area that have also been integrated into the Allpoint surcharge-free ATM network – the largest surcharge-free … Continue reading “RaceTrac Names Cardtronics Exclusive Provider of ATM Services for Dallas-Ft. Worth Stores”

Spero Therapeutics Announces Positive Results from SPR720 IND-Enabling Studies and Plans to Initiate a Phase 1 Trial

CAMBRIDGE, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections, today announced results from preclinical IND-enabling studies of SPR720, an oral antimicrobial agent being developed for the treatment of pulmonary non-tuberculous mycobacterial (NTM) infections. The … Continue reading “Spero Therapeutics Announces Positive Results from SPR720 IND-Enabling Studies and Plans to Initiate a Phase 1 Trial”